Evaluation of the murine immune response to Leishmania meta 1 antigen delivered as recombinant protein or DNA vaccine

Vaccine

Volumn 20, Issue 31-32, 2002, Pages 3755-3763

  Serezani, Carlos Henrique Cardoso ^a   Franco, Amanda Richards ^a   Wajc, Mariana ^a   Umada Yokoyama Yasunaka, Jenicer K ^a   Wunderlich, Gerhard ^a   Borges, Monamaris Marques ^b   Uliana, Silvia Reni Bortolin ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

MCP 3; Meta 1 protein; Vaccine

Indexed keywords

CD4 ANTIGEN; COMPLEMENTARY DNA; DNA VACCINE; FREUND ADJUVANT; LEISHMANIA META 1 ANTIGEN; LEISHMANIA VACCINE; MONOCYTE CHEMOTACTIC PROTEIN 3; PARASITE ANTIGEN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG; CYTOKINE; META1 PROTEIN, LEISHMANIA MAJOR; MONOCYTE CHEMOTACTIC PROTEIN; PROTOZOAL PROTEIN; PROTOZOAL VACCINE; PROTOZOON ANTIBODY; RECOMBINANT PROTEIN; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; GENE; GENE FUSION; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; LEISHMANIASIS; META 1 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROVOCATION TEST; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL LINE; CELL STRAIN COS1; CERCOPITHECUS; CHEMISTRY; GENETICS; IMMUNOLOGY; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; METABOLISM; MOUSE; SKIN LEISHMANIASIS; SOLUBILITY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, PROTOZOAN; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOKINES; FEMALE; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, DIFFUSE CUTANEOUS; MICE; MICE, INBRED BALB C; MONOCYTE CHEMOATTRACTANT PROTEINS; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; SOLUBILITY; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH2 CELLS; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 0036828239     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00354-7     Document Type: Article

References (43)

1. Herwaldt B.L. Leishmaniasis. Lancet. 54(9185):1999;1191-1199.
2. Roberts LS, Janovy JJ. Kinetoplasta: trypanosomes and their kin. In: Roberts LS, Janovy JJ, editors. Foundations of parasitology. New York: McGraw Hill; 2000. p. 55-82.
3. Sharifi I., Fekri A.R., Aflatonian M.R.et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet. 351(9115):1998;1540-1543.
4. Khalil E.A., El Hassan A.M., Zijlstra E.E.et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet. 356(9241):2000;1565-1569.
5. Reiner S.L., Locksley R.M. The regulation of immunity to Leishmania major. Ann. Rev. Immunol. 13:1995;151-177.
6. + T cells. J. Immunol. 165(2):2000;915-924.
7. Kaye P.M., Curry A.J., Blackwell J.M. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146(8):1991;2763-2770.
8. Afonso L.C., Scott P. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun. 61(7):1993;2952-2959.
9. Handman E. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14(2):2001;229-243. and references therein.
10. Champsi J., McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect Immun. 56(12):1988;3272-3279.
11. Stäger S., Smith D.F., Kaye P.M. Immunisation with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol. 165(12):2000;7064-7071.
12. Afrin F., Anam K., Ali N. Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes. J. Parasitol. 86(4):2000;730-735.
13. Ghosh A., Zhang W.W., Matlashewski G. Immunisation with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine. 20(1/2):2001;59-66.
14. Ulmer J.B., Donnelly J.J., Parker S.E.et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259(5102):1993;1745-1749.
15. Pertmer T.M., Roberts T.R., Haynes J.R. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J. Virol. 70(9):1996;6119-6125.
16. Lipford G.B., Bauer M., Blank C., Reiter R., Wagner H., Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27(9):1997;2340-2344.
17. Gurunathan S., Sacks D.L., Brown D.R.et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186(7):1997;1137-1147.
18. Xu D., Liew F.Y. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology. 84(2):1995;173-176.
19. Walker P.S., Scharton-Kersten T., Rowton E.D.et al. Genetic immunisation with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum. Gene. Ther. 9(13):1998;1899-1907.
20. Sjolander A., Baldwin T.M., Curtis J.M., Handman E. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J. Immunol. 160(8):1998;3949-3957.
21. Méndez S., Gurunathan S., Kamhawi S.et al. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 166(8):2001;5122-5128.
22. Rafati S., Salmanian A.H., Taheri T., Vafa M., Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine. 19(25-26):2001;3369-3375.
23. Labrecque S., Matlashewski G. Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine. 19(23-24):2001;3169-3178.
24. Fragaki K., Suffia I., Ferrua B., Rousseau D., Le Fichoux Y., Kubar J. Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters. Vaccine. 19(13-14):2001;1701-1709.
25. Nourbakhsh F., Uliana S.R., Smith D.F. Characterisation and expression of a stage-regulated gene of Leishmania major. Mol. Biochem. Parasitol. 76(1-2):1996;201-213.
26. Uliana S.R., Goyal N., Freymuller E., Smith D.F. Leishmania: overexpression and comparative structural analysis of the stage-regulated meta 1 gene. Exp. Parasitol. 92(3):1999;183-191.
27. Oliveira C.I., Wunderlich G., Levitus G. Antigenic properties of the merozoite surface protein 1 gene of Plasmodium vivax. Vaccine. 17(23-24):1999;2959-2968.
28. Crowley T.E., Bond M.W., Meyerowitz E.M. The structural genes for three Drosophila glue proteins reside at a single polytene chromosome puff locus. Mol. Cell Biol. 3(4):1983;623-634.
29. + T cells. Eur. J. Immunol. 20(12):1990;2533-2540.
30. + effector cells default to the Th2 pathway in interferon γ-deficient mice infected with Leishmania major. J. Exp. Med. 179(4):1994;1367-1371.
31. Hasan U.A., Abai A.M., Harper D.R., Wren B.W., Morrow W.J. Nucleic acid immunisation: concepts and techniques associated with third generation vaccines. J. Immunol. Methods. 229(1-2):1999;1-22.
32. Mougneau E., Altare F., Wakil A.E.et al. Expression cloning of a protective Leishmania antigen. Science. 268(5210):1995;563-566.
33. Biragyn A., Tani K., Grimm M.C., Weeks S., Kwak L.W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. 17(3):1999;253-258.
34. Berberich C., Marin M., Ramirez J.R., Muskus C., Velez I.D. The metacyclic stage-expressed meta-1 gene is conserved between old and new world Leishmania species. Mem. Inst. Oswaldo Cruz. 93(6):1998;819-821.
35. Sjolander A., Baldwin T.M., Curtis J.M., Bengtsson K.L., Handman E. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1-type of immune response but does not protect against infection. Vaccine. 16(20):1998;2077-2084.
36. Gicheru M.M., Olobo J.O., Anjili C.O., Orago A.S., Modabber F., Scott P. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect Immun. 69(1):2001;245-251.
37. Melby P.C., Yang J., Zhao W., Perez L.E., Cheng J. Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69(8):2001;4719-4725.
38. Dumonteil E., Andrade-Narvarez F., Escobedo-Ortegon J.et al. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana. Dev. Biol. (Basel). 104:2000;135-141.
39. Wunderlich G., Moura I.C., del Portillo H.A. Genetic immunisation of BALB/c mice with a plasmid bearing the gene coding for a hybrid merozoite surface protein 1-hepatitis B virus surface protein fusion protects mice against lethal Plasmodium chabaudi PC1 infection. Infect. Immun. 68(10):2000;5839-5845.
40. Boyle J.S., Brady J.L., Lew A.M. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature. 392(6674):1998;408-411.
41. Belperron A.A., Feltquate D., Fox B.A., Horii T., Bzik D.J. Immune responses induced by gene gun or intramuscular injection of DNA vaccines that express immunogenic regions of the serine repeat antigen from Plasmodium falciparum. Infect. Immun. 67(10):1999;5163-5169.
42. Drew D.R., Lightowlers M., Strugnell R.A. Humoral immune responses to DNA vaccines expressing secreted, membrane bound and nonsecreted forms of the Taenia ovis 45W antigen. Vaccine. 18(23):2000;2522-2532. and references therein.
43. Leitenberg D., Bottomly K. Regulation of naive T cell differentiation by varying the potency of TCR signal transduction. Semin. Immunol. 11(4):1999;283-292.